Ingenium Therapeutics
June 16, 2025
Company Presentation
Cell and Gene Therapy and Genome Editing
Ingenium Therapeutics is a clinical-stage biotech company focusing on developing allogenic cell therapy products. Its lead pipeline, Gengleucel is the only NK cell platform which has completed a phase 2 randomized study (IIT) with clinical benefits and long-term safety results for the treatment of R/R AML with upwards of 140 patients treated to date. Phase 2 sponsored study was approved by Korean FDA and phase 2 sponsored US study is being prepared for IND submission to the FDA to assess MRD conversion of AML patients in CR following chemotherapy. It has been FDA Orphan Drug Designated(ODD) for AML in April 2024.
.png)
Company HQ City:
Daejeon
Company HQ State:
Daejeon
Company HQ Country:
Korea, Republic of
Year Founded:
2020
Lead Product in Development:
Gengleucel; memory NK cell therapy for AML
CEO
Mr. Jinok (Kevin) Koh
CEO/Co-Founder
Development Phase of Lead Product
Phase II
Number of Unlicensed Products Looking for Licensing
1
When you expect your next catalyst update?
FDA phase2 pivotal clinical study IND approval (Gengleucel for AML)
What is your next catalyst (value inflection) update?
March, 2026
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}